secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2021-07-14T23:59:59+00:00
Accession:  0001193125-21-214740
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara prices $50M public offering of 8.33M shares at $6.00 each; net proceeds ~$46.8M
--------------------------------------------------------------------------------

- Offering of 8,333,333 shares priced at $6.00/share for gross proceeds of $50M.
- Net proceeds expected to be ~$46.8M after underwriting discounts and offering expenses.
- Underwriters granted 30-day option to purchase up to 1,249,999 additional shares ($7.5M).
- Closing expected July 16, 2021; Morgan Stanley, SVB Leerink, and Cantor are joint book-runners.
- Company is a clinical-stage biotech focused on rare hemoglobin disorders; proceeds for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312521214740/0001193125-21-214740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312521214740/d138853d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-214740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer